Creating a vaccine to prevent Group B Streptococcus infections in newborns
Development of a Group B Streptococcus bioconjugate vaccine
This study is working on a new, affordable vaccine to help protect newborns from Group B Streptococcus, which can cause serious infections, and aims to make it easier to produce so that more babies can benefit, especially in places that need it most.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vaxnewmo, LLC NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11089573 on NIH RePORTER |
What this research studies
This research focuses on developing a bioconjugate vaccine to protect newborns from Group B Streptococcus (GBS), a major cause of severe infections like meningitis and sepsis. The project aims to create a low-cost vaccine that targets the most common GBS serotypes responsible for early and late-onset diseases. By utilizing innovative manufacturing techniques, the researchers hope to simplify the vaccine production process, making it more accessible, especially in low-resource settings. The ultimate goal is to provide a preventive measure that can significantly reduce the incidence of GBS infections in infants.
Who could benefit from this research
Good fit: Ideal candidates for this research are newborns, particularly those at risk of Group B Streptococcus infections, especially in low- and middle-income countries.
Not a fit: Patients who are older than 89 days or those who have already been diagnosed with GBS infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a widely available vaccine that significantly decreases the rates of GBS infections in newborns, saving lives and reducing healthcare costs.
How similar studies have performed: Previous research has shown success with conjugate vaccines for other bacterial pathogens, indicating a promising potential for this novel approach.
Where this research is happening
Saint Louis, United States
- Vaxnewmo, LLC — Saint Louis, United States (Active)
Researchers
- Principal investigator: Harding, Christian — Vaxnewmo, LLC
- Study coordinator: Harding, Christian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.